Fig. 2. Effects of VEGF-A₁₆₄ antibody (ab, 1, 5 μg) injected intracisternally on CFA-induced thermal hyperalgesia. Neither intracisternal administration of 1 μg VEGF-A₁₆₄ antibody nor vehicle affected head withdrawal latency time in CFA-treated rats. However, intracisternal administration of 5 μg VEGF-A₁₆₄ antibody significantly increased head withdrawal latency time in CFA-treated rats. There were six animals in each group. *p<0 .05, VEGF-A₁₆₄ antibody- vs. vehicle-treated group.

Oral Biol Res 2023;47:151~158 https://doi.org/10.21851/obr.47.04.202312.151

© Oral Biol Res